OTC · Biotechnology

Imugene Limited (IUGNF) Stock

$0.10 +0.00% OTC: IUGNF Healthcare

Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths.

Valuation

MetricValue
Price$0.10
Market Cap$41.60M
P/E Ratio-0.40
P/B Ratio0.63
P/S Ratio14.04
EPS (TTM)$-0.32
52-Week High$0.31
52-Week Low$0.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-134.65%
ROA-86.46%
ROCE-124.50%
Gross Margin-65.91%
Operating Margin-1775.00%
Net Margin-1725.00%
Debt/Equity0.12
Current Ratio1.78

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$13.0M$12.0M$5.0M$4.0M
Operating Profit$-18.0M$-38.0M$-40.0M$-154.0M$-71.0M
Net Profit$-18.0M$-38.0M$-38.0M$-150.0M$-69.0M
EPS$-0.13$-0.23$-0.21$-0.72$-0.32
Op Margin-255.3%-292.5%-337.6%-3092.9%-1613.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$72.0M$148.0M$197.0M$151.0M$84.0M
Total Liabilities$7.0M$9.0M$7.0M$33.0M$39.0M
Cash$29.0M$100.0M$153.0M$93.0M$22.0M
Borrowings$0$1.0M$1.0M$2.0M$11.0M

Latest News

Imugene raises $11.1 million to advance azer-cel after complete responses in early cohort Proactive · Jul 7, 2026 Imugene reports second BTKi cohort response - ICYMI Proactive · Jul 4, 2026 Imugene CEO details azer-cel trial milestone - ICYMI Proactive · Jul 2, 2026 Imugene CEO on Phase 1b azer-cel data: second complete response Proactive · Jul 1, 2026 Imugene reports second complete response in azer-cel BTKi cohort Proactive · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-13.0M$-31.0M$-30.0M$-102.0M$-76.0M
Investing Cash Flow$-16.0M$-1.0M$2.0M$-14.0M$-27.0M
Financing Cash Flow$0$-8.0M$-5.0M$-4.0M$-3.0M
Net Cash Flow$-1.0M$70.0M$53.0M$-60.0M$-71.0M
Free Cash Flow$-19.0M$-31.0M$-30.0M$-109.0M$-90.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.59
FCF Yield-135.46%
Quick Ratio1.68
Interest Coverage-531.75
Return 1Y-52.38%
Return 3Y-95.48%
Return 5Y—

Ownership

Insiders Held10.28%
Institutions Held3.97%
Institutions Float Held4.43%
Institutional HolderSharesReport Date
Cassady Schiller Wealth Management, LLC10,0002023-12-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BSEMBioStem Technologies, Inc. $4.01 +4.59% -3.40 $68.11M 0.00%
CLTEFClara Technologies Corp. $0.06 -91.43% -23.94 $3.60M 0.00%
HSCHFH-Source Holdings Ltd. $0.00 — 0.00 $1176 0.00%
KNTPFKintor Pharmaceutical Limited $0.23 -0.20% -3.33 $107.85M 0.00%
MSCLFSatellos Bioscience Inc. $6.25 +11.81% -1.75 $96.62M 0.00%

About Imugene Limited

Imugene Limited, an Australian firm specializing in clinical-stage immuno-oncology, is dedicated to conceiving diverse immunotherapies. Its core mission involves activating the immune systems of cancer patients to effectively combat and eradicate malignant growths. The company's primary therapeutic candidate is HER-Vaxx, a vaccine engineered for HER2-positive cancers. This treatment operates by stimulating a broad polyclonal antibody response against HER2/neu receptors, specifically addressing gastric and breast cancers. Currently, HER-Vaxx is undergoing Phase 1b/2 clinical evaluation for its application in gastric cancer. Beyond its lead product, Imugene is also advancing PD1-Vaxx, another cancer vaccine designed to induce the body to generate polyclonal antibodies that block PD-1 signaling. Additionally, they are developing CF33, a potent oncolytic virus constructed from a unique combination of genomic sequences sourced from various vaccinia virus strains. Imugene has forged a research collaboration with Celularity Inc. to integrate its CD19 oncolytic virus technology with Celularity's CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19, for the treatment of solid tumors. Furthermore, the company maintains a strategic partnership with Eureka Therapeutics, Inc. Established in 1986, Imugene Limited is headquartered in Sydney, Australia.

Imugene Limited is headquartered in AU.

Imugene Limited (IUGNF) stock trades at $0.10 with a market capitalization of $41.60M. The stock is valued at a price-to-earnings (P/E) ratio of -0.40, price-to-book of 0.63, price-to-sales of 14.04. Over the past 52 weeks the stock has ranged between $0.06 and $0.31, and currently trades 67.7% below its 52-week high.

On profitability, Imugene Limited generates a return on equity (ROE) of -134.65%, return on capital employed of -124.50%, an operating margin of -1775.00%, a net profit margin of -1725.00%.

Official website: www.imugene.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides